Dr. Pfleger Arzneimittel GmbH

Dr. Pfleger Arzneimittel GmbH is a medium-sized pharmaceutical company with over 400 employees and a sales turnover of 110 million in 2020. Dr. Pfleger markets over 60 non-prescription and prescription medicines for indications in urology, gyneacology, dermatology and areas of self-medication in Germany and selected territories world-wide. A milestone for the companys success was its development of the spasmolytic drug Spasmex. Other important medicines include Bicalutin, for the treatment of advanced prostate carcinomas, and Urtimed, for allergic rhinitis and urticaria. The pain reliever Neuralgin, ipalat throat pastilles, the antimycotic drug Mykosert, and the extensive Bio-H-Tin range of products for hair and nails, have established themselves as strong brands in German pharmacies. With the launch of Elmiron Dr. Pfleger has the first approved medicine in Germany for the treatment of chronic bladder pain (interstitial cystitis). Dr. Pfleger exports to around 40 countries, where...